Top Gene-Editing Stocks for Long-Term Investors – Motley Fool
Motley Fool |
Top Gene-Editing Stocks for Long-Term Investors
Motley Fool Editas owns the license to a group of patents for CRISPR-Cas9 and CRISPR–Cpf1 from the Broad Institute and Harvard College. CRISPR Therapeutics and Intellia licensed patents from the University of California. In 2017, the Broad Institute won a big … |
